MAPK3 and Noonan syndrome: Cell culture experiments suggest a gain-of-function effect of Noonan syndrome-associated PTPN11 variants, primarily through releasing auto-inhibition of SHP2 domain activity, resulting in heightened ERK1/2 signaling.